Decipher

DEVICE2 trials

Sponsors

GenomeDx Biosciences Corp, University of Michigan Rogel Cancer Center

Conditions

Prostate Cancer

Unknown Phase

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

CompletedNCT02080689

GenomeDx Biosciences CorpProstate Cancer

Start: 2014-05-31End: 2017-02-01Updated: 2017-02-27

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Active, not recruitingNCT04396808

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2020-11-05End: 2031-03-01Updated: 2026-09-09

Related Papers

Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.

2021-07-2024 citations

Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.

Journal of Clinical Oncology2018-02-202 citations

Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.

Journal of Clinical Oncology2017-02-201 citations

Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.

Journal of Clinical Oncology2016-05-20

Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.

Journal of Clinical Oncology2016-05-20